We are live on !
Find out more
BCM
Burrage Capital Management Portfolio holdings
AUM
$100M
Turnover
36.67%
1-Year Est. Return
66.05%
This Fund
S&P 500
This Quarter Est. Return
+15.05%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$100M
AUM Growth
-$23.7M
(-19%)
Cap. Flow
-$25.4M
Cap. Flow % of AUM
Cap. Flow %
-25.46%
Top 10 Holdings %
Top 10 Hldgs %
70.67%
Holding
30
New
3
Increased
3
Reduced
2
Closed
8
Avg Time Held
Equity + Options
0.8
years
Top 10 Avg Time Held
Equity + Options
0.4
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amicus Therapeutics
FOLD
|
+$4.88M |
| 2 |
Verastem
VSTM
|
+$2.45M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
+$2.3M |
| 4 |
Revolution Medicines
RVMD
|
+$1.75M |
| 5 |
Inozyme Pharma
INZY
|
+$1.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protalix BioTherapeutics
PLX
|
+$9.48M |
| 2 |
PTC Therapeutics
PTCT
|
+$7.59M |
| 3 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$5.17M |
| 4 |
Tvardi Therapeutics
TVRD
|
+$3.91M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$3.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
BioCryst Pharmaceuticals
BCRX
$2.06B
| $13.7M | 13.71% |
864,916
| – | – |
2020 Q4
2 quarters
|
|
2
Intellia Therapeutics
NTLA
$1.62B
| $10.3M | 10.33% |
63,634
| – | – |
2020 Q4
2 quarters
|
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $6.95M | 6.97% |
836,802
+272,247
| +48% | +$2.3M |
2019 Q4
6 quarters
|
|
4
DELISTED
ESSA Pharma
EPIX
| $6.78M | 6.8% |
237,442
| – | – |
2021 Q1
1 quarter
|
|
5
NeoGenomics
NEO
$2.11B
| $6.68M | 6.7% |
147,921
| – | – |
2019 Q4
6 quarters
|
|
6
Lite Strategy Inc
LITS
$35.3M
| $6.64M | 6.66% |
116,566
| – | – |
2019 Q4
6 quarters
|
|
7
DELISTED
Crinetics Pharmaceuticals
CRNX
| $5.55M | 5.57% |
294,620
+22,227
| +8% | +$391K |
2019 Q4
6 quarters
|
|
8
Cytokinetics
CYTK
$8.71B
| $4.84M | 4.85% |
244,673
| – | – |
2020 Q1
5 quarters
|
|
|
9
DELISTED
Amicus Therapeutics
FOLD
| $4.82M | 4.83% |
+500,000
| New | +$4.88M |
2021 Q2
0 quarters
|
|
10
Harmony Biosciences
HRMY
$2.19B
| $4.23M | 4.25% |
150,000
| – | – |
2021 Q1
1 quarter
|
|
|
11
DELISTED
Inozyme Pharma
INZY
| $4.13M | 4.14% |
242,517
+73,044
| +43% | +$1.27M |
2020 Q4
2 quarters
|
|
12
DELISTED
Y-mAbs Therapeutics
YMAB
| $3.87M | 3.88% |
114,454
| – | – |
2019 Q4
6 quarters
|
|
13
Mirum Pharmaceuticals
MIRM
$5.34B
| $3.56M | 3.57% |
205,866
| – | – |
2020 Q4
2 quarters
|
|
14
ADC Therapeutics
ADCT
$184M
| $3.04M | 3.05% |
124,875
| – | – |
2020 Q2
4 quarters
|
|
|
15
Verastem
VSTM
$781M
| $2.87M | 2.88% |
+58,799
| New | +$2.45M |
2021 Q2
0 quarters
|
|
16
DELISTED
Merus
MRUS
| $2.75M | 2.76% |
130,683
| – | – |
2020 Q2
4 quarters
|
|
17
Geron
GERN
$771M
| $2.7M | 2.7% |
1,912,673
| – | – |
2021 Q1
1 quarter
|
|
18
Tectonic Therapeutic
TECX
$413M
| $2.18M | 2.18% |
20,410
| – | – |
2020 Q4
2 quarters
|
|
|
19
Revolution Medicines
RVMD
$39B
| $1.59M | 1.59% |
+50,000
| New | +$1.75M |
2021 Q2
0 quarters
|
|
20
Black Diamond Therapeutics
BDTX
$104M
| $1.35M | 1.35% |
110,447
| – | – |
2020 Q4
2 quarters
|
|
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $1.05M | 1.05% |
47,708
-70,000
| -59% | -$1.55M |
2019 Q4
6 quarters
|
|
|
TPTX
22
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $169K | 0.17% |
2,164
-70,000
| -97% | -$5.17M |
2020 Q1
5 quarters
|
|
23
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-80,727
| Closed | -$3.46M | – |
|
|
24
Fulcrum Therapeutics
FULC
$283M
| – | – |
-319,819
| Closed | -$3.77M | – |
|
|
25
PUT
Intellia Therapeutics
NTLA
$1.62B
| – | – |
-630
| Closed | -$46K | – |
|
Similar funds
WCM
CCM
RGM
TCM
RC
AC
QVT
WFWM
Burrage Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Burrage Capital Management held 30 positions worth $100M, down 19% from $123M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Burrage Capital Management withdrew a net $25.4M in Q2 2021, closing 8 positions and reducing 2 holdings. Its most notable exit was Protalix BioTherapeutics, an estimated $9.48M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
Against the trend, Burrage Capital Management opened a new position in Amicus Therapeutics worth $4.82M.
- Burrage Capital Management's largest Q2 2021 buy was Amicus Therapeutics: 500,000 shares worth $4.82M.
- Burrage Capital Management added most to Epizyme, Inc in Q2 2021, an estimated $2.3M increase.
- Burrage Capital Management's biggest Q2 2021 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $5.17M.
- Burrage Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $9.48M.
- Burrage Capital Management's ten largest holdings make up 71% of its $100M portfolio in Q2 2021.
- Burrage Capital Management opened 3 new positions and closed 8 in Q2 2021.
- Burrage Capital Management's portfolio value fell 19% quarter-over-quarter to $100M.
Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.